Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Nasopharyngeal Carcinoma 18 Esophageal Neoplasms 12 Squamous Cell Carcinoma of Head and Neck 11 Esophageal Squamous Cell Carcinoma 11 Uterine Cervical Neoplasms 9 Head and Neck Neoplasms 9 Carcinoma, Non-Small-Cell Lung 9 Pancreatic Neoplasms 8 Stomach Neoplasms 4 Neoplasms 3 Colorectal Neoplasms 3 Recurrence 2 Pancreatic cancer, adult 2 Neoplasm Metastasis 2 Nasopharyngeal Neoplasms 2 Lung Neoplasms 2 Diffuse Intrinsic Pontine Glioma 2 Carcinoma 2 Adenocarcinoma 2 Uterine Cervical Dysplasia 1 Urinary Bladder Neoplasms 1 Squamous Cell Carcinoma of Anal Canal 1 Solid Tumors 1 Solid Tumor 1 Penile Neoplasms 1 Pathologic Complete Response 1 Pancreatic Cancer Resectable 1 Oropharyngeal Neoplasms 1 Nasopharyngeal Diseases 1 NSCLC 1

Interventions

Pemetrexed 14 Carboplatin 13 osimertinib 10 aflutinib 9 Drug Therapy 9 Gefitinib 7 Radiotherapy 6 Docetaxel 6 Cisplatin 6 anlotinib 5 Radiosurgery 5 Paclitaxel 5 pembrolizumab 4 Vinorelbine 4 Gemcitabine 4 tislelizumab 3 icotinib 3 apatinib 3 HM781-36B 3 Erlotinib Hydrochloride 3 toripalimab 2 spartalizumab 2 rezivertinib 2 camrelizumab 2 Tyrosine Kinase Inhibitors 2 Thalidomide 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Platinum 2 Immune Checkpoint Inhibitors 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × NSCLC × nimotuzumab × Clear all

NCT01861223 2014-02-25

Afatinib Plus Nimotuzumb for NSCLC

Samsung Medical Center

Phase 1/2 Unknown

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡